AurkA Inhibitors Enhance the Effects of B-Raf and MEK Inhibitors in Melanoma Treatment

Journal of Translational Medicine - United Kingdom
doi 10.1186/1479-5876-13-s1-p1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evaluation of the Immunologic Impact of RAF Inhibitors to Guide Optimal Combination of RAF Inhibitors and Immunotherapy for the Treatment of Advanced Melanoma

2014English

HDAC Inhibitors Enhance the Immunotherapy Response of Melanoma Cells

Oncotarget
Oncology
2017English

RAF Dimer Inhibition Enhances the Antitumor Activity of MEK Inhibitors in K‐RAS Mutant Tumors

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2020English

Comparison of Responses of Human Melanoma Cell Lines to MEK and BRAF Inhibitors

Frontiers in Genetics
GeneticsMolecular Medicine
2013English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells

Cancer Research
Cancer ResearchOncology
2014English

Effects of RAF Inhibitors on PI3K/AKT Signalling Depend on Mutational Status of the RAS/RAF Signalling Axis

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy